Chemical formula: C₂₂₁H₃₆₆N₇₂O₆₇S Molecular mass: 5,005.76 g/mol PubChem compound: 56928011
Tesamorelin is indicated for the treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients with lipodystrophy. In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF, and subsequently increases IGF-1 and IGFBP-3 levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H01AC06 | Tesamorelin | H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01A Anterior pituitary lobe hormones and analogues → H01AC Somatropin and somatropin agonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| EGRIFTA Powder for solution fot injection | Health Products and Food Branch (CA) | MPI, CA: SPM | |
| EGRIFTA SV Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Tesamorelin is an active ingredient of these brands:
United States (US)
Canada (CA)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
